IDH1 and acute myeloid leukemia: BAY1436032 showed profound antileukemic activity in two separate mutant AML derived xenografts, and it is now under clinical investigation for AML with IDH1 mutations relapsed from or refractory to at least one previous line of therapy (NCT03127735).